Company Profile

AUROBINDO PHARMA LTD.

NSE : AUROPHARMABSE : 524804ISIN CODE : INE406A01037Industry : Pharmaceuticals & DrugsHouse : Aurobindo
BSE880.1532.2 (+3.8 % )
PREV CLOSE (Rs.) 847.95
OPEN PRICE (Rs.) 855.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 174572
TODAY'S LOW / HIGH (Rs.)845.20 883.65
52 WK LOW / HIGH (Rs.)281.15 967.6
NSE879.25 30.75 (+3.62 % )
PREV CLOSE(Rs.) 848.50
OPEN PRICE (Rs.) 853.95
BID PRICE (QTY) 879.25 (2446 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 5774755
TODAY'S LOW / HIGH(Rs.) 845.10 884.35
52 WK LOW / HIGH (Rs.)288.85 967.5

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.02
Dividend Yield(%) 0.34
TTM EPS (Rs.) 45.40
P/E Ratio 19.39
Book Value (Rs.) 246.88
Face Value (Rs.) 1
MCap (Rs. in Mn) 515713.87
Price/Earning (TTM) 16.44
Price/Sales (TTM) 3.54
Price/Book (MRQ) 3.57
PAT Margin (%) 14.07
ROCE (%) 16.05
Incorporation Year : 1986

Management Info :

K Ragunathan - Chairman N Govindarajan - Managing Director

Registered Office :

Address : Plot No. 2,Maitrivihar ,Ameerpet,
Hyderabad,
Telangana-500038

Phone : +91-040-66725000

Website : www.aurobindo.com

Registrar's Details : K FIN Technologies Pvt Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, MCX
NEWS More
12Nov11-12-2020$Aurobindo Pharma gets nod to transfer business undertaking of Auronext Pharma Aurobindo Pharma gets nod to

Aurobindo Pharma’s board has approved the transfer of business undertaking of Auronext Pharma, a wholly owned subsidiary of the company, on a going concern basis, to Eugia Pharma Specialities, another wholly owned step-down subsidiary of the company, through execution of a business transfer agreement. The Board of Directors of the company at its meeting held on November 11, 2020, has, inter alia, considered and approved the same.

The slump sale shall be effective from the date of execution of the binding agreement. The business transfer shall be completed upon satisfaction of customary conditions precedents such as obtaining necessary corporate and regulatory approvals, transfer of employees, contracts, transfer of immovable properties, transition/ novation of licenses and approvals etc. The transaction is expected to be completed by December 31, 2020.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma’s board has approved the transfer of busines..
12Nov11-12-2020$Aurobindo Pharma soars on getting nod to transfer business undertaking of Auronext Pharma Aurobindo Pharma soars on ge

Aurobindo Pharma is currently trading at Rs. 850.40, up by 39.35 points or 4.85% from its previous closing of Rs. 811.05 on the BSE.

The scrip opened at Rs. 815.90 and has touched a high and low of Rs. 858.80 and Rs. 801.35 respectively. So far 253805 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 967.60 on 10-Aug-2020 and a 52 week low of Rs. 281.15 on 23-Mar-2020.

Last one week high and low of the scrip stood at Rs. 858.80 and Rs. 754.15 respectively. The current market cap of the company is Rs. 47522.55 crore.

The promoters holding in the company stood at 52.01%, while Institutions and Non-Institutions held 36.68% and 11.31% respectively.

Aurobindo Pharma’s board has approved the transfer of business undertaking of Auronext Pharma, a wholly owned subsidiary of the company, on a going concern basis, to Eugia Pharma Specialities, another wholly owned step-down subsidiary of the company, through execution of a business transfer agreement. The Board of Directors of the company at its meeting held on November 11, 2020, has, inter alia, considered and approved the same.

The slump sale shall be effective from the date of execution of the binding agreement. The business transfer shall be completed upon satisfaction of customary conditions precedents such as obtaining necessary corporate and regulatory approvals, transfer of employees, contracts, transfer of immovable properties, transition/ novation of licenses and approvals etc. The transaction is expected to be completed by December 31, 2020.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma is currently trading at Rs. 850.40, up by 39.3..
09Nov11-09-2020$Aurobindo Pharma completes acquisition of MViyeS Pharma Ventures Aurobindo Pharma completes a

Aurobindo Pharma has completed acquisition of 100% equity share capital of MViyeS Pharma Ventures (MViyeS) on November 6, 2020. Before acquisition, MViyeS was holding 32.18% shareholding in Eugia Pharma Specialities, a joint venture company in which the company is holding the balance 67.82%. Now, both Eugia Pharma Specialities and MViyeS Pharma Ventures have become 100% subsidiaries of the Company.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma has completed acquisition of 100% equity share..
09Nov11-09-2020$Aurobindo Pharma inches up on completing acquisition of MViyeS Pharma Ventures Aurobindo Pharma inches up o

Aurobindo Pharma is currently trading at Rs. 784.20, up by 4.75 points or 0.61% from its previous closing of Rs. 779.45 on the BSE.

The scrip opened at Rs. 790.00 and has touched a high and low of Rs. 790.00 and Rs. 780.05 respectively. So far 3863 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 967.60 on 10-Aug-2020 and a 52 week low of Rs. 281.15 on 23-Mar-2020.

Last one week high and low of the scrip stood at Rs. 797.45 and Rs. 753.00 respectively. The current market cap of the company is Rs. 45670.98 crore.

The promoters holding in the company stood at 52.01%, while Institutions and Non-Institutions held 36.68% and 11.31% respectively.

Aurobindo Pharma has completed acquisition of 100% equity share capital of MViyeS Pharma Ventures (MViyeS) on November 6, 2020. Before acquisition, MViyeS was holding 32.18% shareholding in Eugia Pharma Specialities, a joint venture company in which the company is holding the balance 67.82%. Now, both Eugia Pharma Specialities and MViyeS Pharma Ventures have become 100% subsidiaries of the Company.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma is currently trading at Rs. 784.20, up by 4.75..
09Nov11-09-2020$Biocon, Aurobindo Pharma and Cyient to see some action today Biocon, Aurobindo Pharma and

Biocon’s subsidiary company -- Biocon Biologics’ board has approved a Rs 1, 125 crore ($150 million) capital injection from Goldman Sachs. As per the terms of the proposed agreement, Goldman Sachs will be issued Optionally Convertible Debentures at a post money equity valuation of $3.94 Billion. The transaction is subject to customary approvals and conditions. This capital injection by Goldman Sachs will enable Biocon Biologics to make prudent investments in R&D, high-quality manufacturing, as well as, establish a global commercial footprint.

Aurobindo Pharma has completed acquisition of 100% equity share capital of MViyeS Pharma Ventures (MViyeS) on November 6, 2020. Before acquisition, MViyeS was holding 32.18% shareholding in Eugia Pharma Specialities, a joint venture company in which the company is holding the balance 67.82%. Now, both Eugia Pharma Specialities and MViyeS Pharma Ventures have become 100% subsidiaries of the Company.

Cyient has received nod from the Foreign Investment Review Board (FIRB) of Australia, and has completed the acquisition of Integrated Global Partners Pty (IG Partners), an Australia-based technology consultancy company. In August 2020, Cyient had said it will acquire Australian consulting firm IG Partners to expand its end-to-end offerings for the local and regional resources sector.

NTPC has commissioned commercial operation of Unit-2 (800 MW) of Lara Super Thermal Power Station Stage-I (2 X 800 MW). With this, the commercial capacity of NTPC and NTPC group will become 51155 MW and 62910 MW respectively.

Tata Motors is aiming to have the widest portfolio of sports utility vehicles (SUVs) in the domestic market, a move aimed at helping the company muster greater market share in the passenger vehicle segment. The auto major, which currently sells models like Nexon and Harrier in the SUV segment, is also looking to overhaul its entire sales, aftersales and service verticals to enhance the overall buying experience for customers.

Cipla is looking at sustaining growth through the pandemic and has decided certain priorities for the coming quarters, including digital adoption and profitable growth. The drug firm has earmarked digital adoption and resilient operations as first of the key priorities for the coming quarters to achieve sustained growth. The company is adopting digital transformation for patient and channel connect to expand access and leverage demand patterns, and is also proactively de-risking the business by diversifying sources for critical active pharmaceutical ingredients (APIs), intermediates and key starting materials (KSMs), and maintaining adequate inventory levels.

Dilip Buildcon has been declared as L-1 bidder for Mine Developer cum Operator (MDO) Contract for Development and Operation of Siarmal Open Cast Project of Mahanadi Coalfield (MCL), a subsidiary of Coal India (CIL) for 25 Years. The Company has emerged as L-1 bidder in the tender floated by MCL for Development and Operation of Siarmal Open Cast Project in the state of Odisha.

Biocon’s subsidiary company -- Biocon Biologics’ board has..
Financials More
Rs. in Millions
QTR Sep 20 ANNUAL 20
Net Profit8015.418727.4
Gross Profit 11292 23777
Operating Profit 12557.629437.6
Net Sales 45243.4132664.8
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Valiant Organics (BSE)
 3174.15 (4.10%)
M.Cap ( in Cr)
4309.46
Procter&Gamble Healt (BSE)
 6339.50 (1.79%)
M.Cap ( in Cr)
10523.18
Abbott India (BSE)
 15305.70 (0.71%)
M.Cap ( in Cr)
32523.54
Sanofi India (BSE)
 8326.50 (1.16%)
M.Cap ( in Cr)
19176.45
Dr. Reddys Lab (BSE)
 4910.95 (1.71%)
M.Cap ( in Cr)
81661.73
Shareholding Pattern More
PROMOTERS 52.01 %
NON-INSTITUTION 11.31 %
MUTUAL FUNDS/UTI 11.02 %
FI/BANKS/INSURANCE 0.17 %
GOVERNMENT 0 %
FII 0 %
F & O Quotes